Skip to main content

Healthy Subject

3
Pipeline Programs
11
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Betta Pharmaceuticals
Betta PharmaceuticalsChina - Hangzhou
1 program
1
BPI-3016Phase 11 trial
Active Trials
NCT03188848Unknown63Est. Dec 2019
Hanlim Pharm
Hanlim PharmKorea - Seoul
1 program
1
Cohort 1: HL217 Ophathalmic Solution QDPhase 11 trial
Active Trials
NCT03650608Completed24Est. Aug 2017
Innovation Pharmaceuticals
1 program
1
SalinePhase 11 trial
Active Trials
NCT03814200Completed14Est. Feb 2019
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
Peripheral blood mononuclear cell apheresisN/A
Legend Biotech
Legend BiotechNJ - Piscataway
1 program
Peripheral blood mononuclear cell apheresisN/A1 trial
Active Trials
NCT04295096Unknown172Est. Mar 2024
Sensimed
SensimedSwitzerland - Etagnières
1 program
Sensimed TriggerfishN/A1 trial
Active Trials
NCT01906502Completed115Est. Apr 2014
Celltrion
CelltrionKorea - Incheon
1 program
CT-P41PHASE_11 trial
Active Trials
NCT06037395Completed154Est. Oct 2022
Hutchmed
HutchmedChina - Hong Kong
1 program
HMPL-523PHASE_11 trial
Active Trials
NCT05318820Completed39Est. Sep 2022
Hua Medicine
Hua MedicineChina - Shanghai
1 program
HMS5552PHASE_11 trial
Active Trials
NCT03158506Completed6Est. Apr 2017
InnoCare
InnoCareChina - Beijing
1 program
Orelabrutinib and placeboPHASE_11 trial
Active Trials
NCT05660720Unknown48Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InnoCareOrelabrutinib and placebo
HutchmedHMPL-523
CelltrionCT-P41
Innovation PharmaceuticalsSaline
Betta PharmaceuticalsBPI-3016
Hua MedicineHMS5552
Hanlim PharmCohort 1: HL217 Ophathalmic Solution QD
Legend BiotechPeripheral blood mononuclear cell apheresis
SensimedSensimed Triggerfish

Clinical Trials (9)

Total enrollment: 635 patients across 9 trials

NCT05660720InnoCareOrelabrutinib and placebo

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Start: Nov 2022Est. completion: Aug 202348 patients
Phase 1Unknown
NCT05318820HutchmedHMPL-523

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Start: Jun 2022Est. completion: Sep 202239 patients
Phase 1Completed
NCT06037395CelltrionCT-P41

Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Start: Oct 2021Est. completion: Oct 2022154 patients
Phase 1Completed
NCT03814200Innovation PharmaceuticalsSaline

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Start: Jan 2019Est. completion: Feb 201914 patients
Phase 1Completed
NCT03188848Betta PharmaceuticalsBPI-3016

Dose Escalating Study of BPI-3016 in Healthy Subjects

Start: May 2017Est. completion: Dec 201963 patients
Phase 1Unknown
NCT03158506Hua MedicineHMS5552

Human Mass Balance Study of HMS5552 in Healthy Subjects

Start: Mar 2017Est. completion: Apr 20176 patients
Phase 1Completed
NCT03650608Hanlim PharmCohort 1: HL217 Ophathalmic Solution QD

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Start: Aug 2016Est. completion: Aug 201724 patients
Phase 1Completed
NCT04295096Legend BiotechPeripheral blood mononuclear cell apheresis

Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product

Start: Apr 2020Est. completion: Mar 2024172 patients
N/AUnknown
NCT01906502SensimedSensimed Triggerfish

24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population

Start: Jul 2013Est. completion: Apr 2014115 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.